Brightspring Health Services, Inc. · NASDAQ:BTSG
Brightspring Health Services — Q1 2025 Earnings Presentation
14 slides from Brightspring Health Services's earnings presentation, May 2, 2025
Slide 1: First Quarter 2025 Earnings Presentation
First Quarter 2025 Earnings Presentation May 2, 2025 1
Slide 2: Forward-Looking Statements; Non-GAAP Financial Information
Forward-Looking Statements; Non-GAAP Financial Information Forward-Looking Statements • potential substantial malpractice or other similar claims; This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking
Slide 3: A leading pharmacy and health care provider in the U.S.
A leading pharmacy and health care provider in the U.S., serving large and growing markets that have significant unmet needs, with high-quality and integrated services that improve outcomes and reduce cost 3
Slide 4: BrightSpring – a Leader in Home & Community Healthcare
BrightSpring – a Leader in Home & Community Healthcare Attractive Markets, Needed Solutions ✓ Serving large and growing healthcare markets of high-cost and complex patient populations – in preferred and lower-cost home and community settings, for high ROI and patient satisfaction Focus on Growth and
Slide 5: BrightSpring Financial Highlights
BrightSpring Financial Highlights First Quarter 2025 (for Continuing Operations) $2,878M 25.9% $131.1M 28.2% Revenue Revenue Growth Adj. EBITDA Adj. EBITDA Growth First Quarter 2025 ($ in millions) Y/Y Growth Pharmacy Solutions Pharmacy Solutions Revenue $2,532 +28.1% acy Hom arm e an Infusion and S
Slide 6: Q1 2025 Revenue and Adjusted EBITDA Results
Q1 2025 Revenue and Adjusted EBITDA Results (for Continuing Operations) ($ in millions) Revenue Total Revenue +25.9% $2,878 $2,286 $346 Provider Services $309 +12.1% Pharmacy Solutions $2,532 $1,977 +28.1% Q1 2024 Q1 2025 ($ in millions) Adjusted EBITDA(1) Adj. EBITDA 4.5% 4.6% margin(1) Total Adjus
Slide 7: Q1 2025 Pharmacy Solutions Segment Performance
Q1 2025 Pharmacy Solutions Segment Performance (for Continuing Operations) ($ in millions) Q1 2025 Revenue Infusion and Specialty Pharmacy Home and Community Pharmacy Pharmacy Solutions +28.1% $2,532 $1,977 $581 Business Metrics $511 +13.6% $1,952 Prescriptions dispensed 10,877 $1,466 +33.2% (thousa
Slide 8: Q1 2025 Provider Services Segment Performance
Q1 2025 Provider Services Segment Performance (for Continuing Operations) ($ in millions) Q1 2025 Revenue Home Health Care Rehab Care Personal Care Provider Services +12.1% $346 $309 $98 Business Metrics $94 +3.4% $70 $67 +4.6% $178 Home Health Care average 30,241 $148 +20.9% +11.6% y/y daily census
Slide 9: Financial Performance: Three Months Ended March 31, 2025
Financial Performance: Three Months Ended March 31, 2025 (for Continuing Operations) Three Months Ended March 31, 2024 vs. Three Months Ended March 31, 2025 Pharmacy Solutions Provider Services Three Months Three Months Three Months Three Months ($ in millions, Change ($ in millions, Change Ended Ma
Slide 10: 2025 Guidance, Excluding Community Living
2025 Guidance, Excluding Community Living 2025 Fiscal Year Guidance Prior Prior Updated FY 20241 FY 2025 Guidance FY 2025 Guidance FY 2025 Guidance2 2 2 ($ in millions) December 31, 2024 Provided January 20, 2025 Provided March 6, 2025 Provided May 2, 2025 $10,050 – $10,500 $10,150 – $10,600 $10,550
Slide 11: De-leveraging Plan and Capital Allocation Priorities
De-leveraging Plan and Capital Allocation Priorities De-leveraging driven by operational performance and capital allocation Proforma Long-Term Pre IPO / Post-Equity and Debt Leverage Ratio • Capex needs: 1% of revenue Leverage Cash Flow Transactions Leverage Ratio (1) by year-end Ratio Target Genera
Slide 12: Appendix
Appendix 12
Slide 13: Continuing Operations Non-GAAP Reconciliations
Continuing Operations Non-GAAP Reconciliations For the Three Months Ended ($ in thousands) March 31, 2024 March 31, 2025 Net (loss) income from Continuing Operations $ (56,027) $ 9,216 Income Tax Benefit (26,504) (240) Interest Expense, net 54,470 41,763 Depreciation and Amortization 39,236 40,832 E
Slide 14: Basic and Diluted Weighted-Average Shares Outstanding Calculation
Basic and Diluted Weighted-Average Shares Outstanding Calculation utilized in calculating Diluted EPS to Adjusted EPS For the Three Months Ended (in thousands) March 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024 March 31, 2025 Pre-IPO Shares (12/31/2023) 117,857 117,857 117,857 117,857
BrightSpring Health Services — Q1 2025 Earnings Presentation on 6ix